Alexion's Strensiq beats expectations

In its 2Q16 financial results, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) raised its full-year guidance for its metabolic programs after sales of hypophosphatasia drug Strensiq asfotase alfa exceeded expectations.

Strensiq sales were $45.1 million in 2Q16, up sequentially from $33.2 million in 1Q16 and beating the $40 million consensus estimate. The company now expects its metabolic franchise to deliver $200-$220 million in 2016 revenues, up from previous guidance of $180-$200 million. ...